Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients (HEPAVAC)
This study has been completed.
Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
Ensemble contre le SIDA
GlaxoSmithKline
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00190242
First received: September 13, 2005
Last updated: December 15, 2011
Last verified: June 2005
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | October 2009 |
| Primary Completion Date: | October 2006 (Final data collection date for primary outcome measure) |